# EDGAR Filing Document

**Accession Number:** 0001644860
**File Stem:** 0001209191-23-002806
**Filing Date:** 2023-1
**Character Count:** 11893
**Document Hash:** b161e490afd15cf1c9edb079cbb3927d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-002806.hdr.sgml**: 20230110

**ACCESSION NUMBER**: 0001209191-23-002806

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230105

**FILED AS OF DATE**: 20230110

**DATE AS OF CHANGE**: 20230110

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Bostjancic John J.
- **CENTRAL INDEX KEY:** 0001644860

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19961
- **FILM NUMBER:** 23521717

**MAIL ADDRESS:**
- **STREET 1:** C/O SEASPINE HOLDINGS CORPORATION
- **STREET 2:** 2302 LA MIRADA DRIVE
- **CITY:** VISTA
- **STATE:** CA
- **ZIP:** 92081
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Orthofix Medical Inc.
- **CENTRAL INDEX KEY:** 0000884624
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **IRS NUMBER:** 000000000
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 3451 PLANO PARKWAY
- **CITY:** LEWISVILLE
- **STATE:** TX
- **ZIP:** 75056
- **BUSINESS PHONE:** 214-937-2000

**MAIL ADDRESS:**
- **STREET 1:** 3451 PLANO PARKWAY
- **CITY:** LEWISVILLE
- **STATE:** TX
- **ZIP:** 75056

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ORTHOFIX INTERNATIONAL N V
- **DATE OF NAME CHANGE:** 19970708

## Ex-24

```

Power of Attorney
Know all by these presents, that the undersigned hereby makes, constitutes and
appoints
each of Patrick L. Keran and John Bostjancic, or either of them acting singly,
and with full power of substitution and re-substitution, the undersigned's true
and lawful attorney-in-fact (each of such persons and their substitutes being
referred to herein as the "Attorney-in-Fact"), with full power to act for the
undersigned and in the undersigned's name, place and stead, in any and all
capacities, to:
1.	Prepare, execute and submit to the SEC, Orthofix Medical Inc. (the
"Company"), and/or any national securities exchange on which the Company's
securities are listed any and all reports (including any amendments thereto) the
undersigned is required to file with the SEC, or which the Attorney-in-Fact
considers it advisable to file with the SEC, under Section 13 or Section 16 of
the Exchange Act or any rule or regulation thereunder, or under Rule 144 under
the Securities Act of 1933 ("Rule 144"), with respect to the any security of the
Company, including Forms 3, 4 and 5, Schedules 13D and 13G, and Forms 144; and
2.	Obtain, as the undersigned's representative and on the undersigned's behalf,
information regarding transactions in the Company's equity securities from any
third party, including the Company and any brokers, dealers, employee benefit
plan administrators and trustees, and the undersigned hereby authorizes any such
third party to release any such information to the Attorney-in-Fact.
The undersigned acknowledges that:

a)	This Power of Attorney authorizes, but does not require, the Attorney-in-Fact
to act in his discretion on information provided to such Attorney-in-Fact
without independent verification of such information;

b)	Any documents prepared or executed by the Attorney-in-Fact on behalf of the
undersigned pursuant to this Power of Attorney will be in such form and will
contain such information as the Attorney-in-Fact, in his discretion, deems
necessary or desirable;

c)	Neither the Company nor the Attorney-in-Fact assumes any liability for the
undersigned's responsibility to comply with the requirements of Section 13 or
Section 16 of the Exchange Act or Rule 144, any liability of the undersigned for
any failure to comply with such requirements, or any liability of the
undersigned for disgorgement of profits under Section 16(b) of the Exchange Act;
and
d)	This Power of Attorney does not relieve the undersigned from responsibility
for compliance with the undersigned's obligations under Section 13 or Section 16
of the Exchange Act, including, without limitation, the reporting requirements
under Section 13 or Section 16 of the Exchange Act.
The undersigned hereby grants to the Attorney-in-Fact full power and authority
to do and perform each and every act and thing requisite, necessary or advisable
to be done in connection with the foregoing, as fully, to all intents and
purposes, as the undersigned might or could do in person, hereby ratifying and
confirming all that the Attorney-in-Fact, or his or her substitute or
substitutes, shall lawfully do or cause to be done by authority of this Power of
Attorney.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 4 or 5 or Schedules 13D or 13G
or Forms 144 with respect to the undersigned's holdings of and transactions in
securities of the Company, unless earlier revoked by the undersigned in a signed
writing delivered to the Attorney-in-Fact. This Power of Attorney revokes all
previous powers of attorney with respect to the subject matter of this Power of
Attorney.
IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney as of
January 5, 2023.

								/s/ John J. Bostjancic
								Signature

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Bostjancic John J.<br><sub>(Last) (First) (Middle)</sub><br>3451 PLANO PARKWAY<br><sub>(Street)</sub><br>LEWISVILLE, TX 75056<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Orthofix Medical Inc. [ OFIX ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-01-05 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_CFO_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 70019<sup>(1)(2)</sup> | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Employee Stock Option (Right to Buy) | <sup>(3)</sup> | 2023-08-01 | Common Stock | 25810<sup>(4)</sup> | $37.67 | D |  |
| Employee Stock Option (Right to Buy) | <sup>(5)</sup> | 2024-01-27 | Common Stock | 26875<sup>(6)</sup> | $34.09 | D |  |
| Employee Stock Option (Right to Buy) | <sup>(7)</sup> | 2027-01-01 | Common Stock | 7417<sup>(8)</sup> | $43.82 | D |  |
| Employee Stock Option (Right to Buy) | <sup>(9)</sup> | 2028-01-01 | Common Stock | 23207<sup>(10)</sup> | $28.85 | D |  |
| Employee Stock Option (Right to Buy) | <sup>(11)</sup> | 2028-04-23 | Common Stock | 2534<sup>(12)</sup> | $23.86 | D |  |
| Employee Stock Option (Right to Buy) | <sup>(13)</sup> | 2029-01-28 | Common Stock | 28777<sup>(14)</sup> | $40.50 | D |  |
| Employee Stock Option (Right to Buy) | <sup>(15)</sup> | 2030-02-28 | Common Stock | 17968<sup>(16)</sup> | $30.44 | D |  |
| Employee Stock Option (Right to Buy) | <sup>(15)</sup> | 2030-02-28 | Common Stock | 9035<sup>(17)</sup> | $36.04 | D |  |

---

### Footnotes:

(1) Includes 27,323 shares of unvested restricted stock units, of which 5,761 unvested restricted stock units vest in equal installments on each of January 28, 2023 and 2024 and 21,562 unvested restricted stock units vest in equal installments on each of February 28, 2023, 2024 and 2025.

(2) Acquired pursuant to the terms of the merger between the Issuer and SeaSpine Holdings Corporation ("SeaSpine") which became effective on January 5, 2023 (the "Merger"), in exchange for 168,198 shares and unvested restricted stock units of SeaSpine, shares having a market value of $22.76 per share at the effective time of the Merger.

(3) The option vested as to 25% of the underlying shares on May 1, 2016 and the remaining 75% vested in twelve substantially equal quarterly installments thereafter.

(4) The option was assumed by Issuer in connection with the Merger and replaced 62,000 SeaSpine options with an exercise price of $15.68.

(5) The option vested as to 25% of the underlying shares on March 31, 2016 and the remaining 75% vested in twelve substantially equal quarterly installments thereafter

(6) The option was assumed by Issuer in connection with the Merger and replaced 64,559 SeaSpine options with an exercise price of $14.19.

(7) The option vested as to 25% of the underlying shares on January 1, 2020 and the remaining 75% vested or vests, as applicable, in twelve substantially equal quarterly installments thereafter.

(8) The option was assumed by Issuer in connection with the Merger and replaced 17,818 SeaSpine options with an exercise price of $18.24.

(9) The option vested as to 25% of the underlying shares on January 1, 2021 and the remaining 75% vested or vests, as applicable, in twelve substantially equal quarterly installments thereafter.

(10) The option was assumed by Issuer in connection with the Merger and replaced 55,746 SeaSpine options with an exercise price of $12.01.

(11) The option fully vested and became exercisable on June 21, 2020.

(12) The option was assumed by Issuer in connection with the Merger and replaced 6,089 SeaSpine options with an exercise price of $9.93.

(13) The option vests as to 25% of the underlying shares on January 28, 2022 and the remaining 75% vests in twelve substantially equal quarterly installments thereafter.

(14) The option was assumed by Issuer in connection with the Merger and replaced 69,128 SeaSpine options with an exercise price of $16.86.

(15) The option vests as to 25% of the underlying shares on February 28, 2023 and the remaining 75% vests in twelve substantially equal quarterly installments thereafter.

(16) The option was assumed by Issuer in connection with the Merger and replaced 43,163 SeaSpine options with an exercise price of $12.67.

(17) The option was assumed by Issuer in connection with the Merger and replaced 21,704 SeaSpine options with an exercise price of $15.00.

**Signature:** /s/ Patrick Keran, attorney-in-fact  
**Date:** 2023-01-10

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**